Bristol Myers to report Q4 IPRD/licensing expense of $18M
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...
Bristol Myers Squibb Co. stock rises Friday, still underperforms market
The stock's fall snapped a two-day winning streak.
FiercePharma5d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/96.Cy8eSqq3.js ...
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Bristol-Myers Squibb's Long-term Dividend Outlook appears Promising
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Pharmaceutical Technology2d
BMS-986484 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...